Maya Honda

3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2020;51:164-174.

The ADC values vary with different diffusion time and vary in correlation with molecular biomarkers, especially Ki-67. Those results suggest that the diffusion time, which should be reported, might be a useful parameter to consider for breast cancer management.

Non-Gaussian diffusion may be associated with prognosis in invasive breast cancer. A higher K may be a marker to help identify patients at an elevated risk of distant metastasis, which could guide subsequent treatment.

DKI, which increases the sensitivity to complex tissue microstructure compared to standard DWI, has been applied in the breast, allowing to increase clinical performance in distinguishing malignant from benign lesions and in predicting prognosis or treatment response in breast cancer.

The purpose of this study was to investigate the diagnostic performance of ultrafast dynamic contrast-enhanced (UF-DCE) MRI after the completion of neoadjuvant systemic therapy (NST) in breast cancer. In this study, MR examinations of 55 post-NST breast cancers were retrospectively analyzed. Residual tumor sizes were measured in the 20th phase of UF-DCE MRI, early and delayed phases of conventional dynamic contrast-enhanced (DCE) MRI, and high spatial-resolution contrast enhanced MRI (UF, early,

Increasing number of publications on advanced DWI over the last decade indicates growing research interest. EUSOBI survey shows that advanced DWI is used primarily in research, not extensively in clinical practice. More research and standardization are needed to integrate advanced DWI into routine breast imaging practice.

Both acquisitions allowed evaluation of breast lesions with good lesion conspicuity and time-intensity-curve smoothness, whereas CS-VIBE was superior to TWIST-VIBE for morphological evaluation of breast lesions and depiction of blood vessels in the breast. Injection rate appears to have a significant impact on semi-quantitative parameters derived from UF-DCE MRI.

Breast magnetic resonance imaging (MRI) is an essential tool for evaluating breast lesions, with dynamic contrast-enhanced (DCE) MRI being considered the reference standard. However, conventional DCE-MRI has limitations, including long scan times, high costs, and variable specificity leading to unnecessary biopsies. Emerging techniques such as ultrafast dynamic contrast-enhanced (UF-DCE) MRI and diffusion-weighted imaging (DWI) have recently received attention as possible alternatives. UF-DCE MR